2014

Psoriasis Treatment: World Drug Market 2013-2023

NEW YORK, Nov. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Psoriasis Treatment: World Drug Market 2013-2023

http://www.reportlinker.com/p01861532/Psoriasis-Treatment-World-Drug-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details
Psoriasis drugs - this new study shows you R&D, opportunities, and potential revenues


What's the future of treating psoriasis? Visiongain's new report gives you revenue predictions from 2013, helping you stay ahead. There you see financial results, R&D trends, opportunities, and potential revenues.

Avoid falling behind, then, missing business or losing influence. In our new report you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess technologies, competitive forces and expected products.

Read on to explore that industry and see what its future market could be worth.

Forecasts from 2013-2023 and other analyses to help you harness opportunities

Besides revenue forecasting to 2023, our new work shows recent results, growth rates, and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). You also get 73 tables, 62 charts, and two interviews.

Gains through knowledge on psoriasis medicines - discover advantages for your work

Why miss data you need? Why struggle to find it? Instead let our analysis guide you through that market's present and future. That understanding could bring you quicker, easier results. Also you gain expertise to show your authority on those dermatological treatments.

Leaders hold knowledge. Use our predictions, then, to help expand your business and give you more influence. Avoid falling behind. Instead try our new report now.

There you hear what's happening in the industry for psoriasis treatments. You also see where needs and money lie from 2013 to 2023, finding how you and your organisation can gain.

The following sections show what you get in that new investigation.

Sales predictions for the world market and submarkets

What're the secrets of that industry's progress and what's its potential? Discover in our report overall world revenue to 2023 for psoriasis treatment by drugs. Also find individual revenue forecasts to 2023 for therapeutic submarkets at world level:
• Biologics (biological drugs)
• Topical treatments
• Small-molecule systemic agents.

How will those markets expand? Which classes of treatment will generate most money? There you assess prospects for revenue growth, seeing where you can gain.

You find sales predictions by product, too, getting feel for how they can succeed.

Revenue predictions for 10 leading products and 4 expected therapies

How will individual drugs perform from 2013 to 2023 at world level? Our report forecasts psoriasis-treating revenues of 10 established brands and four expected medicines. Assess products such as these:

• Humira
• Enbrel
• Stelara
• Remicade
• Apremilast
• Secukinumab
• Ixekizumab.

There discover how high sales can go, to 2023, finding drugs and years with highest predicted growth and revenues. Also you examine competition. You see what's happening there, understanding challenges, trends, competitors, and opportunities.

You find geographical revenue predictions too.

National markets - where will highest revenues and growth occur?

In developed and developing countries, opportunities for pharma companies in psoriasis treatment will occur from 2013. You see where and how.

Our analyses show individual revenue forecasts to 2023 for 11 national markets:
• US
Japan
Germany, France, UK, Italy, and Spain (EU5)
Brazil, Russia, India, and China (BRIC).

There you find countries with highest revenues and potential sales growth. Our work explains. You assess that technology's future, seeing progress and finding what it means, including emerging trends for those medicines.

Events affecting developers, producers, and sellers

The report explains forces affecting that industry and market from 2013, including these:
• Research and development, including that for monoclonal antibodies (mAbs), IL-17, IL-23, TNF, JAK, and CD4 T-cell inhibition, and anti-inflammatory therapy
• Prevalence and causes of that disease, as well as issues for patient populations
• Competition from generic drugs (generics) and novel therapies
• Companies specialising in dermatology - capabilities and emerging trends
• Demands for better treatments - how payers and the industry respond
• Advances in topical drug delivery.

There you explore political, economic, social, and technological questions, assessing advances and outlooks for business. Discover what the present and future hold.

Companies leading that industry and its market value in 2018

From 2013, treatments for that disorder hold potential for investments, medical advances, and higher revenues. Our work predicts the world market for the psoriasis indication will reach $8.9bn in 2018 - rising from $6bn in 2012 - with further expansion to 2023.

See what's possible there - the expected gains. Our report shows you what technologies and players hold greatest potential. In particular, you explore activities of these companies:

• AbbVie
• Johnson & Johnson (J&J)
• Amgen
• Pfizer
• LEO Pharma
• GlaxoSmithKline (GSK)
• Merck & Co.
• Novartis
• Celgene
• Eli Lilly.

Our analysis shows you participants' results, capabilities, and outlooks. Prospects for R&D in that industry are strong, and from 2013 it holds many opportunities for revenue growth. Our work explains that potential, helping you stay ahead.

Information found nowhere else

In particular, then, our new investigation gives you these advantages:
• Revenues to 2023 at world level, with forecasting of 3 submarkets and 14 products - assess prospects for investments and sales
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - investigate countries for revenues and expected growth
• Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, R&D activities, and outlooks for future success.

Psoriasis Treatment: World Drug Market 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.

With that report you are less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Explore progress and possibilities. Also find how you can save time and get recognition for insight.

1. Executive Summary

1.1 What This Report Covers
1.2 Psoriasis Drugs: World Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to Psoriasis

2.1 Understanding Skin
2.2 What is Psoriasis?
2.3 What Causes Psoriasis?
2.3.1 Genetic Factors
2.3.2 Environmental Factors
2.4 World Prevalence of Psoriasis
2.5 How is Psoriasis Treated?
2.5.1 Biologic Drugs
2.5.2 Small-Molecule Systemic Drugs
2.5.3 Topical Therapies
2.6 Classification of Severity

3. The World Drug Market for Psoriasis, 2013-2023

3.1 The World Drug Market for Psoriasis in 2012: Biologic Drugs Dominate In Terms of Revenue
3.2 The World Drug Market for Psoriasis: Overarching Revenue Forecast, 2013-2023
3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Comparison of Revenues and Market Shares to 2023
3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Grouped Revenue Forecast, 2013-2023
3.5 Biologic Drugs for Psoriasis: Blockbuster Revenue in 2012
3.5.1 Biologic Drugs for Psoriasis: Revenue Forecast, 2013-2023
3.6 Topical Therapies for Psoriasis: The Most Commonly Prescribed Treatments
3.6.1 Topical Therapies for Psoriasis: Revenue Forecast, 2013-2023
3.7 Small-Molecule Systemic Treatments for Psoriasis: Why is Revenue Generation Low?
3.7.1 Small Molecule Systemic Treatments for Psoriasis: Revenue Forecast, 2013-2023

4. Leading Drugs of the Psoriasis Treatment Market, 2013-2023

4.1 The Leading Drugs on the Market in 2012: Three Drugs Achieved Blockbuster Success
4.2 Leading Psoriasis Drugs: Comparison of Revenues and Market Shares, 2018 and 2023
4.3 Leading Psoriasis Drugs: Grouped Forecasts 2013-2023
4.4 Humira: Blockbuster Revenue from Psoriasis Indications in 2012
4.4.1 Humira: Revenue Forecast, 2013-2023
4.5 Enbrel: The First Biologic Treatment for Psoriasis, But Will Success Continue?
4.5.1 Study Eases Fear of TNF Inhibitor-Cancer Risk
4.5.2 New Delivery System: A Driver of Growth In Recent Years
4.5.3 Sales of Enbrel in 2012
4.5.4 Enbrel: Revenue Forecast, 2013-2023
4.5.5 Low Threat of Biosimilar Competition for Enbrel
4.6 Stelara: Setting the Standard for New Psoriasis Treatments
4.6.1 Competition for Stelara in the Pipeline
4.6.2 Stelara: Revenue Forecast, 2013-2023
4.7 Remicade: The Third Leading Drug for Psoriasis, But Can It Maintain This Position?
4.7.1 Remicade: Revenue Forecast, 2013-2023
4.8 Daivobet: The Leading Topical Treatment for Psoriasis
4.8.1 Daivobet: Revenue Forecast, 2013-2023
4.9 Soriatane: Open to Generic Competition, But Remains the Leading Small Molecule Treatment for Psoriasis
4.9.1 Soriatane: Revenue Forecast, 2013-2023
4.10 Clobex: Facing Generic Competition
4.10.1 Clobex: Revenue Forecast, 2013-2023
4.11 Neoral: Side Effects Limit Target Patient Population
4.11.1 Neoral: Revenue Forecast, 2013-2023
4.12 Simponi: Struggling to Capture Market Share
4.12.1 Simponi: Revenue Forecast, 2013-2023
4.13 Tazorac: Generic Competition on the Way
4.13.1 Tazorac: Revenue Forecast, 2013-2023
4.14 Promising Compounds in the Pipeline: A Threat of Competition
4.14.1 Apremilast: A Good Safety Profile Means a Large Target Patient Population
4.14.1.1 Apremilast: Revenue Forecast, 2013-2023
4.14.2 Secukinumab: Remarkable Efficacy Means a Large Share of the Psoriasis Drug Market
4.14.2.1 Secukinumab: Revenue Forecast, 2013-2023
4.14.3 Ixekizumab: The Second IL-17 Inhibitor on the Market
4.14.3.1 Ixekizumab: Revenue Forecast, 2013-2023
4.14.4 MK-3222 (Tildrakizumab): A Lower Risk of Side Effects?
4.14.4.1 MK-3222: Revenue Forecast, 2013-2023

5. The Leading National Markets for Psoriasis Treatment, 2013-2023

5.1 The Leading National Markets in 2012: The US Dominates the Psoriasis Drug Market
5.2 The Leading National Markets: Comparison of Revenues and Market Shares to 2023
5.3 The Leading National Markets: Grouped Revenue Forecasts 2013-2023
5.4 The US: Large Population and Large Financial Resources Mean There is a Large Market for Psoriasis Drugs
5.4.1 The US Psoriasis Drug Market: Revenue Forecast 2013-2023
5.5 The EU5 Psoriasis Drug Market 2012-2023
5.5.1 The Psoriasis Drug Market in Germany: Revenue Forecast, 2013-2023
5.5.2 The Psoriasis Drug Market in France: Revenue Forecast, 2013-2023
5.5.3 The UK Psoriasis Drug Market: Revenue Forecast, 2013-2023
5.5.4 The Italian Psoriasis Drug Market: Revenue Forecast, 2013-2023
5.5.5 The Spanish Psoriasis Drug Market: Revenue Forecast, 2013-2023
5.6 Japan: The Second Largest National Market in 2012, But Will It Remain So?
5.6.1 The Japanese Psoriasis Drug Market: Revenue Forecast 2013-2023
5.7 China: The Psoriasis Drug Market Is Growing Rapidly
5.7.1 The Chinese Psoriasis Drug Market: Revenue Forecast 2013-2023
5.8 India: Low Healthcare Spending Limits the Market
5.8.1 The Indian Psoriasis Drug Market: Revenue Forecast 2013-2023
5.9 Russia: A Market Poised For Expansion
5.9.1 The Russian Psoriasis Drug Market: Revenue Forecast 2013-2023
5.10 Brazil: A Dermatology System to Rival That of the US, But Is This Reflected in the Psoriasis Drug Market?
5.10.1 The Brazilian Psoriasis Drug Market: Revenue Forecast 2013-2023

6. Psoriasis: R&D Pipeline, 2013

6.1 Biologics: Promising Compounds in the Pipeline, 2013
6.1.1 The IL-17 Inhibitors: Secukinumab, Ixekizumab and Brodalimumab
6.1.2 Merck's MK-3222: A Potential First-in-Class Therapy
6.1.3 UCB's Cimzia: Label Expansion to Include Psoriasis?
6.2 Small Molecule Systemic Treatments: Promising Compounds in the Pipeline, 2013
6.2.1 Celgene's Apremilast: A Potential Competitor for the Biologics?
6.2.2 Pfizer's Xeljanz: A First-In-Class Treatment, But Does This Mean Success?
6.2.3 Can-Fite Biopharma's CF-101: Will Inferior Efficacy Limit Sales?
6.2.4 Isotechnika's Voclosporin: An Enhanced Version of Cyclosporine
6.3 Topical Treatments: Promising Compounds in the Pipeline, 2013
6.3.1 Almirall's LAS41002: Awaiting Approval in the EU
6.3.2 Pfizer's Tofacitinib Ointment: Converting a Small Molecule to a Topical Treatment, And to Good Effect
6.3.3 Anacor Pharmaceuticals' AN2728: A Phosphodiesterase-4 Inhibitor with a Novel Route of Administration
6.3.4 Creabilis Therapeutics' CT327: A Novel Treatment for Psoriasis Through the Blockade of Neurogenic Inflammation

7. Leading Companies in the Psoriasis Treatment Market, 2013

7.1 The Leading Companies in the Market
7.2 AbbVie, Previously Abbott, Leads the Psoriasis Drug Market in Terms of Revenue
7.3 Johnson & Johnson: With 3 of the Leading Products for Psoriasis in its Portfolio, J&J Claims a Large Share of the Market
7.4 Amgen: 5% of Revenue Generated by Psoriasis Treatment
7.5 Pfizer: A Strong Pipeline Means Share of the Psoriasis Drug Market Will Increase in the Future
7.6 LEO Pharma: A Specialist in Dermatology
7.7 GSK: Limited Revenue from Existing Psoriasis Drugs, But New Treatments on the Way
7.8 Merck: A Modest Share of the Market in 2012
7.9 Novartis: The World's Leading Pharmaceutical Company, But Where Does it Rank in the Psoriasis Drug Market?
7.10 Celgene: Entering the Psoriasis Drug Market in 2014
7.11 Eli Lilly: How Will Competition Affect the Company's Entrance to the Market?

8. Qualitative Analysis of the Psoriasis Treatment Industry, 2013-2023

8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2013
8.1.1 Strengths Stem From High Demand for Treatment and High Revenue Potential
8.1.2 Weaknesses Stem From Patient Dissatisfaction with Treatment
8.2 The Opportunities and Threats Facing the Psoriasis Drug Market, 2013-2023
8.2.1 Opportunities Stem From the Demand for Novel Therapies, But What Are the Criteria For Success?
8.2.2 Competition, Safety Concerns and Poor Patient Compliance: Threats to the Industry
8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP Analysis), 2013-2023
8.3.1 Social Factors Influencing the Market
8.3.2 Advances in Technology Will Continue to Drive Growth
8.3.3 Advances in Topical Drug Delivery Methods
8.3.4 Technological Advances Mean Personalised Medicine for Psoriasis is a Real Possibility
8.3.5 Economic Pressures Differ in Different Territories, Both Driving and Restraining Growth
8.3.6 Political Factors: Drivers or Restraints?

9. Research Interviews

9.1 Interview with Dr Jashin J. Wu, M.D., F.A.A.D., Director of Dermatology Research at Kaiser Permanente Los Angeles Medical Center
9.1.1 On the Current State of the Psoriasis Drug Market
9.1.2 On the Potential of Pipeline Products
9.1.3 On the Use and Future of Biologic Therapies
9.1.4 On the Drivers, Challenges and Future of the Psoriasis Drug Market
9.2 Interview With Prof. Dr. Sergio Chimenti, Professor and Chairman, Department of Dermatology, University of Rome Tor Vergata.
9.2.1 On the Success of Current Treatments for Psoriasis
9.2.2 On the Psoriasis Drug Pipeline
9.2.3 On Topical Treatments for Psoriasis, Now and in the Future
9.2.4 On the Challenges Surrounding Psoriasis Treatment
9.2.5 On Drivers of the Psoriasis Drug Market

10. Conclusions

10.1 The World Market Value for Psoriasis Drugs, 2013-2023
10.2 Leading Drugs of the Psoriasis Treatment Market, 2013-2023
10.3 Leading National Markets for Psoriasis Drugs, 2013-2023
10.4 Leading Companies in the Industry
10.5 Trends in the Industry and Market

List of Tables

Table 2.1 Biologic Drugs Indicated for the Treatment of Psoriasis, 2013
Table 2.2 Small Molecule Systemic Drugs Indicated for the Treatment of Psoriasis, 2013
Table 2.3 Topical Therapies Indicated for the Treatment of Psoriasis, 2013
Table 3.1 The Psoriasis Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2012
Table 3.2 The World Drug Market for Psoriasis: Revenue Forecast ($m), 2012-2023
Table 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Revenue ($m) and Market Share (%) Predictions, 2018 and 2023
Table 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Revenue Forecasts ($m), 2012-2023
Table 3.5 Biologic Drugs for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.6 Topical Therapies for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 3.7 Small Molecule Systemic Treatments for Psoriasis: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.1 The Top 10 Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2012
Table 4.2 Leading Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2018 and 2023
Table 4.3 Leading Psoriasis Drugs: Grouped Revenue Forecasts ($m), 2012-2023
Table 4.4 Humira: Key Facts
Table 4.5 Humira: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.6 Enbrel: Key Facts
Table 4.7 Enbrel: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.8 Stelara: Key Facts
Table 4.9 Stelara: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.10 Remicade: Key Facts
Table 4.11 Remicade: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.12 Daivobet/ Dovobet/ Taclonex: Key Facts
Table 4.13 Daivobet/ Dovobet/ Taclonex: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.14 Soriatane: Key Facts
Table 4.15 Soriatane: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.16 Clobex: Key Facts
Table 4.17 Clobex: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.18 Neoral: Key Facts
Table 4.19 Neoral: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.20 Simponi: Key Facts
Table 4.21 Simponi: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.22 Tazorac: Key Facts
Table 4.23 Tazorac: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.24 Apremilast: Key Facts
Table 4.25 Apremilast: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.26 Secukinumab: Key Facts
Table 4.27 Secukinumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.28 Ixekizumab: Key Facts
Table 4.29 Ixekizumab: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 4.30 MK-3222: Key Facts
Table 4.31 MK-3222: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.1 The Leading National Markets for Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2012
Table 5.2 The Leading National Markets for Psoriasis Drugs: Revenues ($m) and Market Shares (%), 2018 and 2023
Table 5.3 The Leading National Markets for Psoriasis Drugs: Grouped Revenue Forecasts ($m), 2012-2023
Table 5.4 The US Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.5 The EU5 Psoriasis Drug Markets: Grouped Revenue Forecasts ($m), 2012-2023
Table 5.6 The German Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.7 The French Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.8 The UK Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.9 The Italian Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.10 The Spanish Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.11 The Japanese Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.12 The Chinese Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.13 The Indian Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.14 The Russian Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 5.15 The Brazilian Psoriasis Drug Market: Revenue ($m) and Market Share (%) Forecast, 2012-2023
Table 6.1 Biologic Drugs in the Pipeline for Psoriasis and Psoriatic Arthritis, 2013
Table 6.2 Small Molecule Systemic Treatments: Promising Compounds in the Pipeline, 2013
Table 6.3 Topical Treatments: Promising Compounds in the Pipeline, 2013
Table 7.1 The Leading Companies in the Psoriasis Drug Market: Revenue ($m) and Market Share (%), 2012
Table 7.2 AbbVie: Breakdown of Revenue by Sales of Humira for Psoriasis Indications (%), 2012
Table 7.3 J&J: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis Indications, 2012
Table 7.4 Amgen: Breakdown of Revenue ($m, %) by Sales of Enbrel for Psoriasis Indications, 2012
Table 7.5 Pfizer: Breakdown of Revenue ($m, %) by Sales of Enbrel for Psoriasis Indications, 2012
Table 7.6 LEO Pharma: Revenue ($m) from Drugs for Psoriasis, 2012
Table 7.7 GSK: Breakdown of Revenue ($m, %) by Sales of Drugs for Psoriasis, 2012
Table 7.8 Merck: Breakdown of Revenue by Drug and Indication ($m, %), 2012
Table 7.9 Novartis: Breakdown of Revenue by Sales of Drugs for Psoriasis ($m, %), 2012
Table 8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2013
Table 8.2 Opportunities and Threats Facing the Psoriasis Drug Market, 2013-2023
Table 8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP Analysis), 2013-2023
Table 8.4 Medicare Part D and the "Donut Hole": Total Drug Spend ($), Out-of-Pocket Costs (%) and Coverage by Medicare (%), 2013
Table 10.1 Drivers and Restraints of the Psoriasis Drug Market, 2013-2023

List of Figures

Figure 3.1 The Psoriasis Drug Market by Therapeutic Class: Market Shares (%), 2012
Figure 3.2 The World Drug Market for Psoriasis: Revenue Forecast ($m), 2012-2023
Figure 3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Market Shares (%), 2018
Figure 3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Market Shares (%), 2023
Figure 3.5 Biologic Drugs: Share (%) of the Psoriasis Drug Market, 2012
Figure 3.6 Biologic Drugs for Psoriasis: Revenue Forecast ($m), 2012-2023
Figure 3.7 Topical Treatments: Share (%) of the Psoriasis Drug Market, 2012
Figure 3.8 Topical Therapies for Psoriasis: Revenue Forecast ($m), 2012-2023
Figure 3.9 Small Molecule Systemic Treatments: Share (%) of the Psoriasis Drug Market, 2012
Figure 3.10 Small Molecule Systemic Treatments for Psoriasis: Revenue Forecast ($m), 2012-2023
Figure 4.1 The Leading Psoriasis Drugs: Market Shares (%), 2012
Figure 4.2 The Leading Psoriasis Drugs: Market Shares (%), 2018
Figure 4.3 The Leading Psoriasis Drugs: Market Shares (%), 2023
Figure 4.4 Humira: Revenue Forecast ($m), 2012-2023
Figure 4.5 Enbrel: Revenue Forecast ($m), 2012-2023
Figure 4.6 Stelara: Revenue Forecast ($m), 2012-2023
Figure 4.7 Remicade: Revenue Forecast ($m), 2012-2023
Figure 4.8 Daivobet/ Dovobet/ Taclonex: Revenue Forecast ($m), 2012-2023
Figure 4.9 Soriatane: Revenue Forecast ($m), 2012-2023
Figure 4.10 Clobex: Revenue Forecast ($m), 2012-2023
Figure 4.11 Neoral: Revenue Forecast ($m), 2012-2023
Figure 4.12 Simponi: Revenue Forecast ($m), 2012-2023
Figure 4.13 Tazorac: Revenue Forecast ($m), 2012-2023
Figure 4.14 Apremilast: Revenue Forecast ($m), 2012-2023
Figure 4.15 Secukinumab: Revenue Forecast ($m), 2012-2023
Figure 4.16 Ixekizumab: Revenue Forecast ($m), 2012-2023
Figure 4.17 MK-3222: Revenue Forecast ($m), 2012-2023
Figure 5.1 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2012
Figure 5.2 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2018
Figure 5.3 The Leading National Markets for Psoriasis Drugs: Market Shares (%), 2023
Figure 5.4 The US Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.5 The US Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.6 The EU5 Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.7 The EU5 Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.8 The German Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.9 The French Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.10 The UK Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.11 The Italian Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.12 The Spanish Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.13 The Japanese Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.14 The Japanese Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.15 The Chinese Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.16 The Chinese Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.17 The Indian Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.18 The Indian Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.19 The Russian Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.20 The Russian Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 5.21 The Brazilian Psoriasis Drug Market: World Market Share (%), 2012
Figure 5.22 The Brazilian Psoriasis Drug Market: Revenue Forecast ($m), 2012-2023
Figure 6.1 Overview of R&D Pipeline for Psoriasis Drugs: Candidates in Phase III Trials, 2013
Figure 7.1 The Leading Companies in the Psoriasis Drug Market: Market Shares (%), 2012
Figure 7.2 AbbVie: Breakdown of Revenue by Indication (%), 2012
Figure 7.3 Johnson & Johnson: Breakdown of Revenue by Indication (%), 2012
Figure 7.4 Amgen: Breakdown of Revenue by Indication (%), 2012
Figure 7.5 Pfizer: Breakdown of Revenue by Indication (%), 2012
Figure 7.6 GSK: Breakdown of Revenue by Indication (%), 2012
Figure 7.7 Merck: Breakdown of Revenue by Indication (%), 2012
Figure 7.8 Novartis: Breakdown of Revenue by Indication (%), 2012
Figure 10.1 The World Market for Psoriasis Drugs by Therapeutic Category ($m), 2012-2023
Figure 10.2 The Leading Drugs of the Psoriasis Drug Market: Comparison of Revenue ($m), 2013, 2018 and 2023
Figure 10.3 The Leading National Markets: Comparison of Revenue ($m), 2013, 2018 and 2023
Figure 10.4 The Leading Companies in the Industry: Comparison of Revenue Generated by Sales of Drugs for Psoriasis ($m), 2012

Companies Listed

Abbott Laboratories
AbbVie
AbGenomics
Actavis
Actelion
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
ApoPharma
Astellas
AstraZeneca
Basilea Pharmaceutica
Bayer
Biocon
Biotest
Brazilian Society of Dermatology
Bristol-Myers Squibb
Can-Fite Biopharma
Celgene
Celltrion
Centocor Ortho Biotech
Creabilis Therapeutics
Eisai
Eli Lilly
European Medicines Association (EMA)
Food and Drug Administration (FDA)
Fortuderm
Forward-Pharma
Galapagos
Galderma Laboratories
GlaxoSmithKline (GSK)
Hanwha Pharma
Immunex
Incyte
Isotechnika
Janssen Biotech
Johnson & Johnson (J&J)
Kaiser Permanente Los Angeles Medical Center
LEO Pharma
Maruho North America
Medicare
Merck & Co.
Mitsubishi Tanabe Pharma
Mycenax Biotech
Novartis
Pfizer
Sandoz
Sirtris
Stiefel Laboratories
Takeda Pharmaceuticals
Teva Pharmaceutical industries
Therapeutics Inc.
UCB
University of Rome Tor Vergata
VBL Therapeutics
Warner Chilcott
Watson Pharmaceuticals (now part of Actavis)
World Bank
Wyeth (now part of Pfizer)

To order this report: Psoriasis Treatment: World Drug Market 2013-2023
http://www.reportlinker.com/p01861532/Psoriasis-Treatment-World-Drug-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication


Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.